Vibegron has entered NICE recommendations for overactive bladder without ever being compared directly against mirabegron, the older beta-3 agonist. This network meta-analysis connected them indirectly, identifying five phase III randomised trials with 5,317 patients for the primary outcome.
Vibegron showed greater improvement in urgency episodes than placebo, tolterodine and mirabegron, and also ranked favourably for urgency incontinence episodes and maximum voided volume per void. Mirabegron ranked better for reduction in urinary frequency over 24 hours. On adverse events, any adverse event was most frequent with vibegron, as was constipation; tolterodine had the highest rates of hypertension and dry mouth; and mirabegron was least associated with hypertension.
Two cautions belong with these rankings. The authors note large heterogeneity in how adverse events were defined and reported across trials, so the safety comparisons are the least reliable part — and hypertension is precisely the outcome that matters most when choosing between beta-3 agonists. And the analysis explicitly does not account for contraindications, swallowing difficulty, or what is actually available and affordable, which in most settings determines the choice more than a ranking does. Useful for framing a discussion; not a substitute for the head-to-head trial that still has not been done.
- Vibegron ranked best for urgency, urgency incontinence and voided volume
- Mirabegron ranked best for urinary frequency and lowest for hypertension
- Any adverse event and constipation highest with vibegron
- Adverse event definitions varied widely — safety rankings are the weakest part
The statistics, in plain English
Network meta-analysis infers comparisons that were never made directly, by linking trials through shared comparators — here mostly placebo and tolterodine. That inference is only as good as the assumption that the trials enrolled similar patients, which five trials cannot demonstrate. Rankings are also less informative than they look: a drug can rank first while its advantage is too small to notice, and the analysis reports ranks rather than effect sizes for most outcomes.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free